Green Thumb Industries (GTBIF) Non-Current Deferred Tax Liability (2019 - 2026)
Green Thumb Industries' (GTBIF) quarterly Non-Current Deferred Tax Liability came in at $220.6 million in Q1 2026, up 180.58% YoY from $78.6 million in Q1 2025, and little changed on a QoQ basis from $220.6 million in Q4 2025.
Green Thumb Industries (GTBIF) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 8 years of Non-Current Deferred Tax Liability data on file, last reported at $220.6 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 180.58% year-over-year to $220.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $220.6 million (up 180.58% YoY) and the FY2025 annual result came in at $220.6 million, up 180.58% from the prior year.
- Non-Current Deferred Tax Liability steadied at $220.6 million in Q1 2026, from $220.6 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $220.6 million in Q4 2025 to a low of $62.6 million in Q4 2022.
- A 5-year average of $90.6 million and a median of $78.6 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability fell 23.58% — and 2025, when it jumped 180.58%.
- Tracing GTBIF's Non-Current Deferred Tax Liability over 5 years: stood at $62.6 million in 2022, then grew by 15.92% to $72.5 million in 2023, then climbed by 8.43% to $78.6 million in 2024, then jumped by 180.58% to $220.6 million in 2025, then changed by 0.0% to $220.6 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $220.6 million (Q1 2026), $220.6 million (Q4 2025), and $78.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Green Thumb Industries | 1.69 Bn | 1.41 Bn | 137.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.14 Mn |
| Jun 30, 2026 | 17.14 Mn |
| Mar 31, 2026 | 220.60 Mn |
| Mar 31, 2026 | 220.60 Mn |
| Dec 31, 2025 | 220.60 Mn |
| Dec 31, 2025 | 220.60 Mn |
| Sep 30, 2025 | 78.62 Mn |
| Sep 30, 2025 | 78.62 Mn |
| Jun 30, 2025 | 78.62 Mn |
| Jun 30, 2025 | 78.62 Mn |
| Mar 31, 2025 | 78.62 Mn |
| Mar 31, 2025 | 78.62 Mn |
| Dec 31, 2024 | 78.62 Mn |
| Dec 31, 2024 | 78.62 Mn |
| Sep 30, 2024 | 72.51 Mn |
| Sep 30, 2024 | 72.51 Mn |
| Jun 30, 2024 | 72.51 Mn |
| Jun 30, 2024 | 72.51 Mn |
| Mar 31, 2024 | 72.51 Mn |
| Mar 31, 2024 | 72.51 Mn |